HAS-BLED Score Calculator

HAS-BLED is a bleeding risk assessment tool for patients with atrial fibrillation on anticoagulation. It evaluates nine factors: Hypertension (+1), Abnormal renal/liver function (+1 each), Stroke (+1), Bleeding history (+1), Labile INR (+1), Elderly > 65 (+1), Drugs/alcohol (+1 each). Score ≥ 3 indicates high bleeding risk requiring attention to modifiable factors.

Each component contributes 1 point, except renal and liver disease (counted as 1 point each) and drugs/alcohol (counted as 1 point each, max 2). Hypertension = SBP > 160 mmHg. Abnormal renal = dialysis, transplant, Cr > 2.26 mg/dL. Abnormal liver = cirrhosis or bilirubin > 2x normal with AST/ALT > 3x normal. Labile INR = TTR < 60%. Drugs = antiplatelets or NSAIDs.

A HAS-BLED score ≥ 3 indicates high bleeding risk, with annual major bleeding rate of approximately 3.7–22% depending on the exact score. However, a high score should NOT automatically preclude anticoagulation. Instead, it triggers a careful assessment of modifiable risk factors to minimize bleeding risk while maintaining stroke prevention.

From the original validation: Score 0 = 0.6%, 1 = 1.0%, 2 = 1.9%, 3 = 3.7%, 4 = 5.5%, 5 = 8.0%, 6 = 11.5%, 7 = 15.0%, 8 = 18.5%, 9 = 22.0% annual major bleeding risk. These rates vary by population and anticoagulant used (NOACs have lower ICH rates than warfarin at equivalent scores).

No. A high HAS-BLED score should not prevent anticoagulation, as the net clinical benefit of stroke prevention in AFib typically outweighs the bleeding risk. The ESC guidelines emphasize that a high HAS-BLED score should prompt identification and management of modifiable risk factors, not withholding anticoagulation.

CHA₂DS₂-VASc and HAS-BLED share overlapping risk factors (age, hypertension, stroke). Patients with high stroke risk often have high bleeding risk. The net clinical benefit of anticoagulation is generally positive even at high HAS-BLED scores, because ischemic strokes cause more death/disability than anticoagulant-related bleeds.

Modifiable risk factors include: hypertension (SBP > 160) — treat with antihypertensives; labile INR — improve warfarin management, consider switching to NOAC; excessive alcohol use — reduce or eliminate; concurrent NSAIDs or antiplatelets — discontinue if possible; and renal disease — adjust NOAC dose, monitor renal function.

Non-modifiable risk factors include: age > 65 (elderly), prior stroke history, prior bleeding history, and liver disease (cirrhosis). These factors cannot be reversed but should be considered in the overall risk-benefit assessment. Their presence may favor NOACs over warfarin (lower ICH risk).

Labile INR is defined as time in therapeutic range (TTR) < 60% for patients on warfarin. Unstable INRs increase both bleeding and thrombotic risk. Causes include poor compliance, drug interactions, dietary vitamin K fluctuations, and genetic factors (VKORC1, CYP2C9 variants). Switching to a NOAC eliminates labile INR as a bleeding risk factor.

Hypertension in HAS-BLED is defined as systolic blood pressure > 160 mmHg. This threshold is higher than the general HTN definition (> 140/90) and reflects the specific bleeding risk from poorly controlled blood pressure. Uncontrolled HTN is a modifiable risk factor — treating to < 140/90 reduces bleeding risk.

Abnormal renal function is defined as: chronic dialysis, renal transplantation, or serum creatinine ≥ 2.26 mg/dL (200 µmol/L). Renal impairment increases bleeding risk through impaired drug clearance (especially dabigatran and rivaroxaban) and uremic platelet dysfunction. NOAC dose adjustments are required for CrCl < 30–50 depending on the drug.

Abnormal liver function is defined as: chronic liver disease (e.g., cirrhosis) or biochemical evidence of significant hepatic impairment (bilirubin > 2x upper limit of normal with AST/ALT > 3x upper limit of normal). Liver disease increases bleeding risk due to reduced synthesis of clotting factors and portal hypertension.

"Drugs" refers to concurrent use of antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor) or NSAIDs (ibuprofen, naproxen, diclofenac, etc.). These medications increase bleeding risk by impairing platelet function and/or causing GI mucosal injury. Whenever possible, these should be discontinued when starting anticoagulation.

"Alcohol" refers to excessive alcohol consumption, typically defined as > 8 drinks per week. Alcohol increases bleeding risk through liver dysfunction (reduced clotting factor synthesis), portal hypertension, increased risk of falls, and potential non-adherence to anticoagulation. Reduction or cessation is strongly recommended.

HAS-BLED was developed in a warfarin cohort. For NOACs, the absolute bleeding rates at each score are lower, especially for intracranial hemorrhage (52% relative risk reduction with NOACs vs warfarin). However, the relative ranking of risk by score remains valid. A high HAS-BLED score may favor NOACs over warfarin due to their better safety profile.

HAS-BLED was developed and validated in AFib patients. However, it is sometimes used in VTE patients on anticoagulation as a general bleeding risk assessment. Specific VTE bleeding risk scores (e.g., VTE-BLEED) may be more appropriate for post-PE/DVT patients. Use HAS-BLED cautiously in non-AFib populations.

Age > 65 adds 1 point in HAS-BLED. Age > 75 is a stronger predictor of bleeding (2–3 fold increase vs age < 65). Elderly patients have higher bleeding risk due to renal impairment, frailty, fall risk, polypharmacy, and amyloid angiopathy (increased ICH risk). Despite higher bleeding risk, elderly patients derive the greatest absolute stroke risk reduction from anticoagulation.

GI bleeding is the most common major bleed (0.5–1.5% per year with NOACs, higher with rivaroxaban and edoxaban). Intracranial hemorrhage (ICH) is the most feared (0.2–0.5% per year with NOACs, lower than warfarin). Other bleeds include hematuria, epistaxis, skin bruising, and intramuscular hematomas.

For minor GI bleeding, hold anticoagulation, identify and treat the source (PPI for gastritis, endoscopic intervention for ulcers). For major GI bleeding, reverse anticoagulation if needed (idarucizumab for dabigatran, andexanet alfa for rivaroxaban/apixaban, PCC for edoxaban). After stabilization, reassess the need for anticoagulation and consider GI prophylaxis (PPI).

Intracranial hemorrhage (ICH) is bleeding within the brain parenchyma, ventricles, or subdural/subarachnoid spaces. It is the most serious complication of anticoagulation, with 50% mortality and high disability among survivors. Risk factors include age, HTN, prior stroke, and concurrent antiplatelets. ICH risk is 0.2–0.5%/yr with NOACs vs 0.5–1.0%/yr with warfarin.

Emergency management: reverse anticoagulation (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors, PCC + vitamin K for warfarin), control BP (< 140/90), neurosurgical consultation for evacuation if indicated. After ICH, restarting anticoagulation is controversial — typically withheld for 4–8 weeks, then consider LAA occlusion or reduced-dose NOAC.

Proton pump inhibitors (PPIs) reduce the risk of upper GI bleeding in patients on anticoagulation, especially those with additional risk factors (NSAID use, prior GI bleed, age > 65, H. pylori infection). Guidelines recommend PPI co-therapy for patients with GI bleeding risk factors who require anticoagulation.

Major bleeding rates in landmark NOAC trials: apixaban 2.13%/yr, rivaroxaban 3.6%/yr, edoxaban 2.75%/yr, dabigatran 150 mg 3.11%/yr, dabigatran 110 mg 2.71%/yr. For comparison, warfarin major bleeding rates were 3.09–3.4%/yr. Intracranial hemorrhage rates are consistently lower with NOACs (0.2–0.5%/yr vs 0.5–1.0%/yr for warfarin).

Each NOAC has specific renal dose adjustments: apixaban 5 mg BID (reduce to 2.5 mg BID if any 2 of: age ≥ 80, weight ≤ 60 kg, Cr ≥ 1.5); dabigatran 150 mg BID (reduce to 110/75 mg BID if CrCl 30–50, contraindicated if < 30); rivaroxaban 20 mg QD (reduce to 15 mg QD if CrCl 15–50); edoxaban 60 mg QD (reduce to 30 mg QD if CrCl 15–50).

Idarucizumab (Praxbind) is a humanized monoclonal antibody fragment that binds dabigatran with high affinity, providing immediate and complete reversal. Dose: 5 g IV (two 2.5 g vials). Reversal occurs within minutes and lasts 12–24 hours. It is indicated for life-threatening bleeding or need for emergency surgery.

Andexanet alfa (Andexxa) is a modified recombinant factor Xa decoy that neutralizes rivaroxaban and apixaban (also edoxaban and enoxaparin). Dose: 400–800 mg IV bolus + infusion depending on timing of last dose. It is approved for life-threatening or uncontrolled bleeding. PCC (4-factor) and aPCC (FEIBA) are used as alternatives when andexanet is unavailable.

The risk-benefit assessment compares: (1) ischemic stroke risk without anticoagulation (CHA₂DS₂-VASc) vs (2) major bleeding risk with anticoagulation (HAS-BLED). For most patients with CHA₂DS₂-VASc ≥ 2, the number needed to treat to prevent one stroke is 20–50, while the number needed to harm for one major bleed is 50–100. Net clinical benefit strongly favors anticoagulation.

Anticoagulation should be withheld in: active major bleeding, severe thrombocytopenia (< 50,000), recent ICH, coagulopathy (INR > 3.0 not on warfarin), recent major surgery with high bleeding risk (CNS, spinal, cardiac), and severe liver disease with coagulopathy. Temporary interruption is required for procedures with high bleeding risk.

Left atrial appendage occlusion (LAAO) with Watchman or Amulet devices is a non-pharmacologic stroke prevention strategy. Indications include: patients at high bleeding risk (HAS-BLED ≥ 3), prior major bleed on anticoagulation, labile INR, occupational risk (frequent falls), or patient preference to avoid long-term anticoagulation. After LAAO, short-term DAPT or anticoagulation is needed for 45–180 days.

Bleeding risk should be reassessed at each clinical encounter, especially after: hospitalization, change in renal/hepatic function, addition of antiplatelets or NSAIDs, change in anticoagulant type or dose, new diagnosis of malignancy, or bleeding event. HAS-BLED score can change as risk factors are modified or new ones develop.